Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Next Previous
Trial Profile

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-052
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 25 Sep 2024 According to a Merck & Co media release, the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved new indications for KEYTRUDA (pembrolizumab), monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.
  • 24 Oct 2023 Results of post hoc pooled analysis (n=49) assessing the efficacy and safety outcomes with pembrolizumab rechallenge for patients with advanced/metastatic urothelial cancer from KEYNOTE-045, KEYNOTE-052 and KEYNOTE-361 trials, presented at the 48th European Society for Medical Oncology Congress.
  • 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top